

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| | |
|--|---|
| <p style="text-align: center;">Licensee</p> <p>1. Central Vermont Medical Center</p> <p>2. P.O. Box 547 Barre, Vermont 05641</p> | <p>In accordance with the letter dated October 21, 2013,</p> <p>3. License number 44-13353-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date November 30, 2022</p> <hr/> <p>5. Docket No. 030-03292 Reference No.</p> |
|--|---|

| | | |
|--|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Sealed sources (Best Medical International, Inc. Models 2301 and 2335; Medi-Physics, Inc. d/b/a GE Healthcare or Amersham Health OncoSeed Model 6711; BEBIG Isotopentechnik und Umweltdiagnostik Model I25.S06; Bard Brachytherapy Inc. Model STM 1251; IsoAid, L.L.C. Models IAI-125A and IAPd-103A; Core Oncology Inc. Models I-125 SL and I-125 SH; North American Scientific, Inc. Models MED3631 and MED3633; Nucletron B.V. Model selectSeed I-125 130.002; Theragenics Corporation TheraSeed Model 200 and I-Seed Models I25.S06 and AgX100)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1.5 curies</p> |
|--|---|--|

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
44-13353-01

Docket or Reference Number
030-03292

Amendment No. 24

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any manual brachytherapy procedure permitted by 10 CFR 35.400, for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at Central Vermont Medical Center, 130 Fisher Road, Berlin, Vermont.
- 11. The Radiation Safety Officer for this license is Marleen M. Moore, M.S.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

| <u>Authorized Users</u> | <u>Material and Use</u> |
|-------------------------------|-------------------------|
| Daniel K. Fram, M.D. | 35.400 |
| H. James Wallace, M.D. | 35.400 |
| Joseph Pekala, M.D. | 35.100; 35.200 |
| Robert D. Johnson, M.D. | 35.100; 35.200 |
| Mark R. Heitzman, M.D. | 35.100; 35.200 |
| Charles Nicholas Pappas, M.D. | 35.100; 35.200 |

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
44-13353-01

Docket or Reference Number
030-03292

Amendment No. 24

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated May 30, 2012 [ML12167A287]
- B. Letter dated September 18, 2012 [ML12269A470]
- C. Letter dated November 26, 2012 [ML12334A122]
- D. Letter received December 17, 2013



For the U.S. Nuclear Regulatory Commission

Date December 24, 2013

By *Penny Lanzisera*
 Penny Lanzisera
 Medical Branch
 Division of Nuclear Materials Safety
 Region I
 King of Prussia, Pennsylvania 19406